Lianna J Marks1, Qinglin Pei2, Rizvan Bush3, Allen Buxton3, Burton Appel4, Kara M Kelly5, Cindy L Schwartz6, Debra L Friedman7. 1. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Children's Oncology Group Statistics & Data Center, University of Florida, Gainesville, Florida. 3. Children's Oncology Group Statistics and Data Center, Monrovia, California. 4. Department of Pediatrics, Hackensack University Medical Center, Hackensack, New Jersey. 5. Department of Pediatrics, Roswell Park Cancer Institute, Buffalo, New York. 6. Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin. 7. Department of Pediatrics, Vanderbilt University, Nashville, Tennessee.
Abstract
PURPOSE: Optimal management of patients with intermediate-risk lymphocyte-predominant Hodgkin lymphoma (LPHL) is unclear due to their small numbers in most clinical trials. Children's Oncology Group AHOD0031, a randomized phase III trial of pediatric patients with intermediate-risk Hodgkin lymphoma (HL), included patients with LPHL. We report the outcomes of these patients and present directions for future therapeutic strategies. PROCEDURE: Patients received two cycles of doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) followed by response evaluation. Slow early responders were randomized to two additional ABVE-PC cycles ± two dexamethasone, etoposide, cisplatin, and cytarabine cycles and all received involved field radiotherapy (IFRT). Rapid early responders (RERs) received two additional ABVE-PC cycles. RERs with complete response (CR) were randomized to IFRT or no further therapy. RERs without CR received IFRT. RESULTS: Ninety-six (5.6%) of 1711 patients on AHOD0031 had LPHL. Patients with LPHL were more likely to achieve RER (93.6% vs. 81.0%; P = 0.002) and CR (74.2% vs. 49.3%; P = 0.000005) following chemotherapy compared with patients with classical HL. Five-year event-free survival (EFS) was superior in patients with LPHL (92.2%) versus classical HL (83.5%) (P = 0.04), without difference in overall survival (OS). Among RERs with CR following chemotherapy (n = 33), there was no difference in EFS or OS between those randomized to receive or not receive IFRT. CONCLUSION:Children and adolescents with intermediate-risk LPHL represent ideal candidates for response-adapted therapy based on their favorable outcomes. The majority of patients treated with the ABVE-PC backbone achieve RER with CR status and can be treated successfully without IFRT.
RCT Entities:
PURPOSE: Optimal management of patients with intermediate-risk lymphocyte-predominant Hodgkin lymphoma (LPHL) is unclear due to their small numbers in most clinical trials. Children's Oncology Group AHOD0031, a randomized phase III trial of pediatric patients with intermediate-risk Hodgkin lymphoma (HL), included patients with LPHL. We report the outcomes of these patients and present directions for future therapeutic strategies. PROCEDURE: Patients received two cycles of doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) followed by response evaluation. Slow early responders were randomized to two additional ABVE-PC cycles ± two dexamethasone, etoposide, cisplatin, and cytarabine cycles and all received involved field radiotherapy (IFRT). Rapid early responders (RERs) received two additional ABVE-PC cycles. RERs with complete response (CR) were randomized to IFRT or no further therapy. RERs without CR received IFRT. RESULTS: Ninety-six (5.6%) of 1711 patients on AHOD0031 had LPHL. Patients with LPHL were more likely to achieve RER (93.6% vs. 81.0%; P = 0.002) and CR (74.2% vs. 49.3%; P = 0.000005) following chemotherapy compared with patients with classical HL. Five-year event-free survival (EFS) was superior in patients with LPHL (92.2%) versus classical HL (83.5%) (P = 0.04), without difference in overall survival (OS). Among RERs with CR following chemotherapy (n = 33), there was no difference in EFS or OS between those randomized to receive or not receive IFRT. CONCLUSION:Children and adolescents with intermediate-risk LPHL represent ideal candidates for response-adapted therapy based on their favorable outcomes. The majority of patients treated with the ABVE-PC backbone achieve RER with CR status and can be treated successfully without IFRT.
Authors: M A Weiner; B Leventhal; M L Brecher; R B Marcus; A Cantor; P W Gieser; J L Ternberg; F G Behm; M D Wharam; A R Chauvenet Journal: J Clin Oncol Date: 1997-08 Impact factor: 44.544
Authors: T A Lister; D Crowther; S B Sutcliffe; E Glatstein; G P Canellos; R C Young; S A Rosenberg; C A Coltman; M Tubiana Journal: J Clin Oncol Date: 1989-11 Impact factor: 44.544
Authors: S Bodis; M D Kraus; G Pinkus; B Silver; M E Kadin; G P Canellos; L N Shulman; N J Tarbell; P M Mauch Journal: J Clin Oncol Date: 1997-09 Impact factor: 44.544
Authors: Timothy C Griffin; Sheila Weitzman; Howard Weinstein; Myron Chang; Mitchell Cairo; Robert Hutchison; Bruce Shiramizu; Joseph Wiley; Deborah Woods; Margaret Barnich; Thomas G Gross Journal: Pediatr Blood Cancer Date: 2009-02 Impact factor: 3.167
Authors: James B Nachman; Richard Sposto; Philip Herzog; Gerald S Gilchrist; Suzanne L Wolden; John Thomson; Marshall E Kadin; Paul Pattengale; P Charlton Davis; Raymond J Hutchinson; Keith White Journal: J Clin Oncol Date: 2002-09-15 Impact factor: 44.544
Authors: Ranjana H Advani; Sandra J Horning; Richard T Hoppe; Sarah Daadi; John Allen; Yasodha Natkunam; Nancy L Bartlett Journal: J Clin Oncol Date: 2014-02-10 Impact factor: 44.544
Authors: Mubarak Al-Mansour; Joseph M Connors; Randy D Gascoyne; Brian Skinnider; Kerry J Savage Journal: J Clin Oncol Date: 2010-01-04 Impact factor: 44.544
Authors: Kevin C Oeffinger; Kayla L Stratton; Melissa M Hudson; Wendy M Leisenring; Tara O Henderson; Rebecca M Howell; Suzanne L Wolden; Louis S Constine; Lisa R Diller; Charles A Sklar; Paul C Nathan; Sharon M Castellino; Dana Barnea; Susan A Smith; Raymond J Hutchinson; Gregory T Armstrong; Leslie L Robison Journal: J Clin Oncol Date: 2021-02-25 Impact factor: 50.717